Save on Zytiga with Coupons, Discounts & Savings Programs

Zytiga is the brand name for abiraterone and is available as an oral tablet.

Zytiga is available as 250 mg and 500 mg oral tablet.

Zytiga is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with:

• metastatic castration-resistant prostate cancer (CRPC)
• metastatic high-risk castration-sensitive prostate cancer (CSPC)

Zytiga works by interrupting the androgen-making process at an important step. It inhibits androgen at 3 sources—the testes, the adrenal glands, AND the tumor itself.

Zytiga is typically taken for:

Metastatic castration-resistant prostate cancer:

• Zytiga 1,000 mg orally once daily with prednisone 5 mg orally twice daily

Metastatic castration-sensitive prostate cancer:

• Zytiga 1,000 mg orally once daily with prednisone 5 mg orally once daily
• Patients receiving Zytiga should also receive a gonadotropin-releasing
• hormone (GnRH) analog concurrently or should have had bilateral orchiectomy
• Zytiga tablets must be taken as a single dose once daily on an empty stomach
• Do not eat food 2 hours before and 1 hour after taking Zytiga. The tablets must be swallowed whole with water. Do not crush or chew tablets

Zytiga is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Zytiga:

• Fatigue
• Arthralgia
• Hypertension
• Nausea
• Edema
• Hypokalemia
• Hot flush
• Diarrhea
• Vomiting
• Upper respiratory infection
• Cough
• Headache

Serious side effects are rare with Zytiga. Some examples include:

• High blood pressure (hypertension), low blood potassium levels (hypokalemia), fluid retention (edema), and irregular heartbeats
• Adrenal problems
• Severe liver problems
• Liver problems.
• Low blood sugar
• Increased risk of bone fracture and death

The following medications may interact with Zytiga:

• CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during Zytiga treatment. If a strong CYP3A4 inducer must be co-administered, increase the Zytiga dosing frequency CYP2D6 Substrates: Avoid co-administration of Zytiga with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate

Janssen Pharmaceuticals

The safety and efficacy of Zytiga have not been established in females. Based on findings from animal studies and the mechanism of action, Zytiga can cause fetal harm and potential loss of pregnancy.

• Abiraterone Acetate